These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30526254)

  • 1. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.
    Lu X; Nobrega RP; Lynaugh H; Jain T; Barlow K; Boland T; Sivasubramanian A; Vásquez M; Xu Y
    MAbs; 2019 Jan; 11(1):45-57. PubMed ID: 30526254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of in vivo site-specific Asp isomerization and Asn deamidation of mAbs in animal serum using IP-LC-MS.
    Mehl JT; Sleczka BG; Ciccimaro EF; Kozhich AT; Gilbertson DG; Vuppugalla R; Huang CS; Stevens B; Mo J; Deyanova EG; Wang Y; Huang RY; Chen G; Olah TV
    Bioanalysis; 2016 Aug; 8(15):1611-1622. PubMed ID: 27397670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures.
    Diepold K; Bomans K; Wiedmann M; Zimmermann B; Petzold A; Schlothauer T; Mueller R; Moritz B; Stracke JO; Mølhøj M; Reusch D; Bulau P
    PLoS One; 2012; 7(1):e30295. PubMed ID: 22272329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualification of a Quantitative Method for Monitoring Aspartate Isomerization of a Monoclonal Antibody by Focused Peptide Mapping.
    Cao M; Mo WD; Shannon A; Wei Z; Washabaugh M; Cash P
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):490-507. PubMed ID: 27091886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based
    Hoffmann D; Bauer J; Kossner M; Henry A; Karow-Zwick AR; Licari G
    MAbs; 2024; 16(1):2333436. PubMed ID: 38546837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants.
    DiCara DM; Andersen N; Chan R; Ernst JA; Ayalon G; Lazar GA; Agard NJ; Hilderbrand A; Hötzel I
    MAbs; 2018 Oct; 10(7):1073-1083. PubMed ID: 30130444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies.
    Wakankar AA; Borchardt RT; Eigenbrot C; Shia S; Wang YJ; Shire SJ; Liu JL
    Biochemistry; 2007 Feb; 46(6):1534-44. PubMed ID: 17279618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Function Assessment and High-Throughput Quantification of Site-Specific Aspartate Isomerization in Monoclonal Antibody Using a Novel Analytical Tool Kit.
    Zhou K; Cao X; Bautista J; Chen Z; Hershey N; Ludwig R; Tao L; Zeng M; Das TK
    J Pharm Sci; 2020 Jan; 109(1):422-428. PubMed ID: 31469998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.
    Azevedo Reis Teixeira A; Erasmus MF; D'Angelo S; Naranjo L; Ferrara F; Leal-Lopes C; Durrant O; Galmiche C; Morelli A; Scott-Tucker A; Bradbury ARM
    MAbs; 2021; 13(1):1980942. PubMed ID: 34850665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering an anti-CD52 antibody for enhanced deamidation stability.
    Qiu H; Wei R; Jaworski J; Boudanova E; Hughes H; VanPatten S; Lund A; Day J; Zhou Y; McSherry T; Pan CQ; Sendak R
    MAbs; 2019 Oct; 11(7):1266-1275. PubMed ID: 31199181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N+1 Engineering of an Aspartate Isomerization Hotspot in the Complementarity-Determining Region of a Monoclonal Antibody.
    Patel CN; Bauer SP; Davies J; Durbin JD; Shiyanova TL; Zhang K; Tang JX
    J Pharm Sci; 2016 Feb; 105(2):512-518. PubMed ID: 26869414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.
    Alam ME; Geng SB; Bender C; Ludwig SD; Linden L; Hoet R; Tessier PM
    Mol Pharm; 2018 Jan; 15(1):150-163. PubMed ID: 29154550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five computational developability guidelines for therapeutic antibody profiling.
    Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A High-Throughput Bioluminescent Assay to Monitor the Deamidation of Asparagine and Isomerization of Aspartate Residues in Therapeutic Proteins and Antibodies.
    Hsiao K; Alves J; Patel R; Adams M; Nashine V; Goueli S
    J Pharm Sci; 2017 Jun; 106(6):1528-1537. PubMed ID: 28263844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Automated and Qualified Platform Method for Site-Specific Succinimide and Deamidation Quantitation Using Low-pH Peptide Mapping.
    Cao M; Xu W; Niu B; Kabundi I; Luo H; Prophet M; Chen W; Liu D; Saveliev SV; Urh M; Wang J
    J Pharm Sci; 2019 Nov; 108(11):3540-3549. PubMed ID: 31374319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developability assessment during the selection of novel therapeutic antibodies.
    Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
    J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody.
    Sreedhara A; Cordoba A; Zhu Q; Kwong J; Liu J
    Pharm Res; 2012 Jan; 29(1):187-97. PubMed ID: 21809161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
    Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
    MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of deamidation and isomerization sites on pharmaceutical recombinant antibody using H(2)(18)O.
    Terashima I; Koga A; Nagai H
    Anal Biochem; 2007 Sep; 368(1):49-60. PubMed ID: 17617368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biophysical properties of the clinical-stage antibody landscape.
    Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.